Press Release
Press Release
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Press Release
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
Poster also details clinical readiness for CLDI-201 and plans to initiate Phase 1 study in…
Press Release
Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
FOR IMMEDIATE RELEASE July 18, 2023 LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)– City of…
Press Release
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium…
Press Release
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from the transaction, before payment of transaction expenses, expected to be up…
Press Release
Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)
LA JOLLA, CALIF (November 7, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company…